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A Transformation: Prostate Adenocarcinoma to Small Cell Carcinoma
Julia Bachler MD PGY1, Internal Medicine
Henry Ford Health System, Detroit, Michigan
Introduction
• Prostate Adenocarcinoma is the most common cancer in males, after
melanoma
• <0.5-2% of these reported cases transform into Small Cell Carcinoma
of the Prostate (SCCP) (1)
• SCCP has an aggressive clinical course and is a clinically distinct
disease from prostate adenocarcinoma (3)

Notable Clinical Features of SCCP
• Rapidly progressive disease, aggressive in nature (1)

• While prostate adenocarcinoma carries a good prognosis with
available therapies, SCCP does not

• Little or no response to androgenic therapy

• 40-50% of men diagnosed with SCCP have a history of
conventional prostate adenocarcinoma although SCCP can arise
de novo (1)

• Signs and symptoms of large prostatic or pelvic soft tissue masses,
bulky lymphadenopathy or involvement or viscera

• Overall, SCCP carries a poor prognosis with poor overall survival
despite modern therapies

• This case representation depicts this rare malignancy, noted in a middle
aged male

Case Presentation
• 57yo with relevant past medical history of stage IV prostate
adenocarcinoma
Oncological timeline:
• Initially presented with fatigue and feeling poor overall
• Diagnosed with Stage IV prostate adenocarcinoma via lymph node biopsy
• At that time, CT imaging showed metastatic disease with lymphadenopathy
in retro peritoneum and pelvis
• Treatment included combined androgenic blockade plus taxotere and
prednisone
• Disease was controlled for a short time but he then began to feel poorly
again after a period of about 24 months
• Repeat lymph node biopsy confirmed transformation from adenocarcinoma
to small cell carcinoma of the prostate

• Serum PSA lower than expected for disease burden that does not
correlate with the effect of any treatments

• High prevalence of lytic bone lesions noted in imaging

• It carries a median survival rate of 1-2 years from date of
diagnosis (2)
• Reports show that the median interval between diagnosis of
prostate cancer and newly diagnosed SCCP is about 25 months
(2)
• Favorable prognostic factors include prostatectomy with
radiation, age <60, absence of metastasis, and a mixed lowgrade prostate adenocarcinoma (2)
• Important to note that it is common for these patients to have a
low PSA out of proportion to extent of disease (2)
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Conclusion
• This case demonstrates the aggressive nature despite standard therapy
for SCCP
• Due to its poor prognosis, this shows that further evaluation and
research of possible therapies are needed. However, the rarity of this
disease process does pose challenges
• Due to the progressive nature, it is critical that these patients have
tissue biopsy with treatment initiation if SCCP is suspected, despite a
low PSA level

Further Diagnostic Workup:
• CT abdomen after SCCP diagnosis showed multiple soft tissue masses in
pelvis and abdomen with increase in lymphadenopathy
• Imaging also notable for osseous metastasis in lumbar spine and femur
• PSA during initial Prostate Adenocarcinoma diagnosis: 58.4 ng/mL
• PSA at SCCP diagnosis: 45.9 ng/mL despite increased severity of disease at
this point in his course
• PSA peak throughout disease course: 160.2
Treatment/Management:
• Initial management of Prostate Adenocarcinoma included androgenic
therapy plus taxotere + prednisone with little response
• For transformation to SCCP, patient received Carboplatin plus Etoposide
which is standard therapy

Discussion
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